Bio-Techne (TECH) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)

Bio-Techne (TECH) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 18.47%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -10.08%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 92.37%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Bio-Techne 11.20 Bn 10.99 Bn 208.29 Mn 125.99%

Historic Data

Download Data
DateValue
Mar 31, 2026 125.99%
Dec 31, 2025 8.94%
Sep 30, 2025 13.65%
Jun 30, 2025 -899.35%
Mar 31, 2025 -53.96%
Dec 31, 2024 27.03%
Sep 30, 2024 -34.11%
Jun 30, 2024 -113.85%
Mar 31, 2024 -30.13%
Dec 31, 2023 -45.08%
Sep 30, 2023 -43.17%
Jun 30, 2023 9.43%
Mar 31, 2023 16.75%
Dec 31, 2022 -30.61%
Sep 30, 2022 30.09%
Jun 30, 2022 615.95%
Mar 31, 2022 32.47%
Dec 31, 2021 56.16%
Sep 30, 2021 106.56%
Jun 30, 2021 -132.34%